TKNO
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Board Member
Alpha Teknova, Inc. (TKNO)Equibles does not estimate personal net worth.
Get an email with a short summary when Alpha Teknova, Inc. publishes a filing, an earnings call transcript or a press release.
Get TKNO alertsStephen Gunstream is recorded as CEO and Board Member at Alpha Teknova, Inc. (TKNO). The newest filing on record that lists Stephen Gunstream as CEO and Board Member at Alpha Teknova, Inc. (TKNO) is dated April 21, 2026. The proxy statement of Alpha Teknova, Inc. reports total compensation of $4,042,515 for Stephen Gunstream in fiscal 2021, including a base salary of $433,800. Disclosed compensation is on record for 2 fiscal years. Stephen Gunstream has spoken on 19 earnings calls and 1 other investor event across 1 company, most recently for Alpha Teknova, Inc. on August 5, 2026. Alpha Teknova, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Alpha Teknova, Inc. includes Matthew Lowell (CFO), Damon Terrill (General Counsel), Brett Robertson (Board Member) and 3 others.
“Good afternoon and thank you everyone for joining us for a second quarter 2026 Jeremy's call. We were very pleased with our performance in the second quarter. Revenue grew 18% compared to the second quarter 2025, exceeding 12 million dollars for the quarter, the highest quarterly revenue in Technova's 30-year history.”
“Good afternoon and thank you everyone for joining us for our first quarter 2026 earnings call. It was a relatively straightforward quarter for us across the board, with revenue and operating expenses delivering in line with or better than our expectations.”
“We're happy to talk to you about TechNova. We really feel like we're at an inflection point in the business. It's been a challenging, you know, last four or five years, but we put ourselves, I think, in a great position for long-term growth here.”
“Good afternoon, and thank you, everyone, for joining us for our fourth quarter and full-year 2025 earnings call. 2025 was another year of strong all-around execution for Technova.”
“Good afternoon, and thank you everyone for joining us for our third quarter 2025 earnings call. We were encouraged by our third quarter results. Revenue increased by 9% compared to the same period last year, making it the fifth consecutive quarter of year-over-year growth.”
Start not stated–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 21, 2026
TKNO
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Alpha Teknova, Inc. (TKNO) | President and Chief Executive Officer | $433,800 | $4,042,515 |
| 2020 | Alpha Teknova, Inc. (TKNO) | President and Chief Executive Officer | $364,038 | $1,718,618 |